Niagen Bioscience (NAGE) Enterprise Value (2015 - 2026)
Niagen Bioscience (NAGE) reported Enterprise Value of -$66.5 million for Q1 2026, down 19.66% year-over-year from -$82.8 million in Q1 2025, and down 2.72% quarter-over-quarter from -$64.8 million in Q4 2025.
Niagen Bioscience (NAGE) Enterprise Value (2015 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 12 years of Enterprise Value data on file, last reported at -$66.5 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$66.5 million, down 19.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.5 million (down 19.66% YoY), and the FY2025 annual result was -$64.8 million, down 45.07% from the prior year.
- Enterprise Value retreated to -$66.5 million in Q1 2026 per NAGE's latest filing, from -$64.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$13.3 million in Q3 2022 and troughed at -$66.5 million in Q1 2026.
- A 5-year average of -$36.4 million and a median of -$27.6 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value jumped 59.94% in 2022, then plunged 116.87% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$20.4 million in 2022, then plunged by 33.68% to -$27.3 million in 2023, then slumped by 63.44% to -$44.7 million in 2024, then plunged by 45.07% to -$64.8 million in 2025, then dropped by 2.72% to -$66.5 million in 2026.
- Business Quant data shows NAGE's Enterprise Value at -$66.5 million in Q1 2026, -$64.8 million in Q4 2025, and -$64.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -584.73 Mn |
| 10 | Niagen Bioscience | 269.32 Mn | 202.77 Mn | 19.98 Mn | -66.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.55 Mn |
| Dec 31, 2025 | -64.79 Mn |
| Sep 30, 2025 | -64.29 Mn |
| Jun 30, 2025 | -60.47 Mn |
| Mar 31, 2025 | -55.62 Mn |
| Dec 31, 2024 | -44.66 Mn |
| Sep 30, 2024 | -32.40 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Mar 31, 2024 | -27.57 Mn |
| Dec 31, 2023 | -27.33 Mn |
| Sep 30, 2023 | -26.77 Mn |
| Jun 30, 2023 | -26.41 Mn |
| Mar 31, 2023 | -23.14 Mn |
| Dec 31, 2022 | -20.44 Mn |
| Sep 30, 2022 | -13.26 Mn |
| Jun 30, 2022 | -17.07 Mn |
| Mar 31, 2022 | -20.99 Mn |
| Dec 31, 2021 | -28.22 Mn |
| Sep 30, 2021 | -33.10 Mn |
| Jun 30, 2021 | -38.78 Mn |